Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 8/20 | 0.45 |
| ▸ | AKT2 | P31751 | 6/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | PRKCB | P05771 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | PRKACB | P22694 | 2/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.39 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | PRKCH | P24723 | 1/20 | 0.39 |
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332167 | 1.00 | AKT1 (0.45) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL3338303 | 0.91 | AKT1 (0.45) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL3331359 | 0.91 | AKT1 (0.49) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL3332316 | 0.91 | AKT1 (0.44) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL3329034 | 0.89 | AKT1 (0.44) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL3338310 | 0.88 | AKT1 (0.38) | AKT1AKT2AKT3ROCK2ACSS2 | |
| SCHEMBL3329753 | 0.86 | ROCK2 (0.50) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL3333282 | 0.85 | AKT1 (0.53) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL28922545 | 0.84 | AKT1 (0.44) | AKT1AKT2AKT3ROCK2ROCK1 | |
| SCHEMBL1527212 | 0.84 | AKT1 (0.44) | AKT1AKT2AKT3ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-9425410-B2 | Organic light-emitting diode | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | AKT1 1236/4885AKT2 1565/4885AKT3 1286/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | AKT1 1236/4885AKT2 1565/4885AKT3 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.